Cingulate (NASDAQ:CING) Trading 0.8% Higher

Cingulate Inc. (NASDAQ:CINGGet Free Report)’s share price rose 0.8% during trading on Monday . The company traded as high as $0.94 and last traded at $0.89. Approximately 72,593 shares were traded during trading, a decline of 77% from the average daily volume of 320,454 shares. The stock had previously closed at $0.88.

Analyst Ratings Changes

Separately, HC Wainwright upped their target price on Cingulate to $8.00 and gave the company a “buy” rating in a report on Friday, January 5th.

View Our Latest Report on Cingulate

Cingulate Stock Down 1.0 %

The stock has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $4.16. The company has a market cap of $4.36 million, a PE ratio of -0.03 and a beta of -0.95.

Institutional Trading of Cingulate

A hedge fund recently bought a new stake in Cingulate stock. Commonwealth Equity Services LLC purchased a new stake in shares of Cingulate Inc. (NASDAQ:CINGFree Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 100,771 shares of the company’s stock, valued at approximately $71,000. Commonwealth Equity Services LLC owned about 0.64% of Cingulate at the end of the most recent reporting period. Institutional investors and hedge funds own 41.31% of the company’s stock.

Cingulate Company Profile

(Get Free Report)

Cingulate Inc, a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults.

Recommended Stories

Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with's FREE daily email newsletter.